Final Draft Guidance Recommends Asfotase alfa (Strensiq) for use for the treatment of Paediatric-onset HPP

1st February 2023

Metabolic Support UK are delighted to share that following a second committee meeting, NICE have now released final draft guidance to recommend the use of Asfotase alfa (Strensiq) for the treatment of all patients with perinatal and infantile forms of paediatric-onset hypophosphatasia and additional recommendations for those with juvenile forms who meet the entry requirements set by the Managed Access Agreement.

Read our historical HPP MAA documents:

Skip to content